Canakinumab in Schnitzler syndrome.

[1]  T. Zuberbier,et al.  Efficacy and safety of the interleukin‐1 antagonist rilonacept in Schnitzler syndrome: an open‐label study , 2012, Allergy.

[2]  G. Kitas,et al.  Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. , 2012, Current pharmaceutical design.

[3]  Donato Rigante,et al.  The fresco of autoinflammatory diseases from the pediatric perspective. , 2012, Autoimmunity reviews.

[4]  J. Schalkwijk,et al.  Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. , 2011, The Journal of allergy and clinical immunology.

[5]  D. Lipsker.  The Schnitzler syndrome , 2010, Orphanet journal of rare diseases.

[6]  E. Besada,et al.  Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review , 2010, Clinical Rheumatology.

[7]  C. Dinarello.  Interleukin-1beta and the autoinflammatory diseases. , 2009, The New England journal of medicine.

[8]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[9]  N. Sepp,et al.  Successful use of anakinra to treat refractory Schnitzler's syndrome. , 2008, Clinical and experimental rheumatology.

[10]  J. V. D. van der Meer,et al.  Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. , 2007, Seminars in arthritis and rheumatism.

[11]  R. Dhôte,et al.  Treatment of Schnitzler's syndrome with anakinra. , 2007, Clinical and experimental rheumatology.

[12]  C. Botsios.  Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. , 2005, Autoimmunity reviews.